Metropolitan Life Insurance Co. NY increased its stake in shares of Rubius Therapeutics Inc (NASDAQ:RUBY) by 320.5% during the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 7,191 shares of the company’s stock after acquiring an additional 5,481 shares during the period. Metropolitan Life Insurance Co. NY’s holdings in Rubius Therapeutics were worth $116,000 as of its most recent filing with the SEC.
Several other hedge funds and other institutional investors also recently modified their holdings of the company. BlackRock Inc. bought a new stake in Rubius Therapeutics during the 3rd quarter valued at approximately $38,155,000. New York State Common Retirement Fund bought a new stake in Rubius Therapeutics during the 4th quarter valued at approximately $116,000. Teachers Advisors LLC bought a new stake in Rubius Therapeutics during the 3rd quarter valued at approximately $563,000. Marshall Wace North America L.P. bought a new stake in Rubius Therapeutics during the 3rd quarter valued at approximately $1,405,000. Finally, Vanguard Group Inc bought a new stake in Rubius Therapeutics during the 3rd quarter valued at approximately $23,329,000. 87.07% of the stock is currently owned by institutional investors and hedge funds.
In other Rubius Therapeutics news, President Torben Straight Nissen sold 2,100 shares of the firm’s stock in a transaction that occurred on Monday, April 8th. The stock was sold at an average price of $20.00, for a total value of $42,000.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Robert Langer sold 7,500 shares of the stock in a transaction that occurred on Monday, April 15th. The stock was sold at an average price of $17.57, for a total value of $131,775.00. The disclosure for this sale can be found here. Insiders sold a total of 70,196 shares of company stock valued at $1,186,015 in the last quarter. Corporate insiders own 58.40% of the company’s stock.
Rubius Therapeutics (NASDAQ:RUBY) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.35) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.42) by $0.07. On average, equities research analysts forecast that Rubius Therapeutics Inc will post -1.71 EPS for the current year.
Separately, Zacks Investment Research downgraded Rubius Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, January 30th. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $30.00.
COPYRIGHT VIOLATION NOTICE: “Metropolitan Life Insurance Co. NY Has $116,000 Stake in Rubius Therapeutics Inc (RUBY)” was originally published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece of content can be viewed at https://www.baseballdailydigest.com/news/2019/04/22/metropolitan-life-insurance-co-ny-has-116000-stake-in-rubius-therapeutics-inc-ruby.html.
About Rubius Therapeutics
Rubius Therapeutics, Inc focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases through its rubius erythrocyte design cellular therapy platform. The company is developing various RCTs, such as RTX-134 for treatment of classic and moderate phenylketonuria; RTX-Uricase/URAT1 for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; RTX-OxOx for the treatment of second-line hyperoxaluria; and RTX-ALAD for the treatment of acute intermittent porphyria.
Further Reading: What is Compound Annual Growth Rate (CAGR)?
Receive News & Ratings for Rubius Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rubius Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.